| Literature DB >> 35173759 |
Tapatee Das1,2, Avijeet Kamle3, Arvind Kumar2,3, Sumana Chakravarty1,2.
Abstract
Understanding the molecular basis of sex differences in neural response to acute hypoxic insult has profound implications for the effective prevention and treatment of ischemic stroke. Global hypoxic-ischemic induced neural damage has been studied recently under well-controlled, non-invasive, reproducible conditions using a zebrafish model. Our earlier report on sex difference in global acute hypoxia-induced neural damage and recovery in zebrafish prompted us to conduct a comprehensive study on the mechanisms underlying the recovery. An omics approach for studying quantitative changes in brain proteome upon hypoxia insult following recovery was undertaken using iTRAQ-based LC-MS/MS approach. The results shed light on the altered expression of many regulatory proteins in the zebrafish brain upon acute hypoxia following recovery. The sex difference in differentially expressed proteins along with the proteins expressed in a uniform direction in both the sexes was studied. Core expression analysis by Ingenuity Pathway Analysis (IPA) showed a distinct sex difference in the disease function heatmap. Most of the upstream regulators obtained through IPA were validated at the transcriptional level. Translational upregulation of H3K9me3 in males led us to elucidate the mechanism of recovery by confirming transcriptional targets through ChIP-qPCR. The upregulation of H3K9me3 level in males at 4 h post-hypoxia appears to affect the early neurogenic markers nestin, klf4, and sox2, which might explain the late recovery in males, compared to females. Acute hypoxia-induced sex-specific comparison of brain proteome led us to reveal many differentially expressed proteins, which can be further studied for the development of novel targets for better therapeutic strategy.Entities:
Keywords: IPA; hypoxia-ischemia recovery; iTRAQ; pathway analysis; sex difference
Year: 2022 PMID: 35173759 PMCID: PMC8841817 DOI: 10.3389/fgene.2021.635904
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
FIGURE 1Analysis of zebrafish brain proteome by iTRAQ. Schematic representation of brain proteome analysis by iTRAQ labeling (A), Cluster heatmap of proteins obtained from iTRAQ analysis for hypoxia male [HM] vs. normoxia male [NM] and hypoxia female [HF] vs. normoxia female [NF] (B), Pie chart showing the analysis of expression of proteins resulted from iTRAQ in hypoxia male and female brain compared with normoxia male and female brain (C).
IPA generated disease function analysis for zebrafish male and female brain proteome induced by hypoxia following recovery.
|
| |||||
| Categories | Diseases or functions annotation |
| Predicted activation state | Activation z-score | # Molecules |
| Organismal survival | Organismal death | 2.31E-11 | Increased | 12.434 | 251 |
| Cell death and survival | Cell death | 2.51E-11 | Increased | 4.843 | 218 |
| Cell death and survival | Necrosis | 3.27E-09 | Increased | 4.131 | 154 |
| Cancer, organismal injury and abnormalities, respiratory disease | Development of lung tumor | 9.13E-08 | Increased | 3.302 | 27 |
| Cancer, organismal injury and abnormalities | Incidence of tumor | 0.000000893 | Increased | 2.199 | 87 |
| Cell death and survival | Apoptosis | 0.000000991 | Increased | 4.38 | 153 |
| Cancer, organismal injury and abnormalities | Malignant genitourinary solid tumor | 0.00000154 | Increased | 2.272 | 33 |
| Cancer, organismal injury and abnormalities | Frequency of tumor | 0.00000449 | Increased | 2.133 | 77 |
| Cancer, organismal injury and abnormalities, respiratory disease | Lung carcinoma | 0.0000213 | Increased | 2.584 | 23 |
| Cancer, organismal injury and abnormalities | Tumorigenesis of epithelial neoplasm | 0.0000284 | Increased | 2.18 | 52 |
| Cancer, organismal injury and abnormalities | Development of adenocarcinoma | 0.0000307 | Increased | 2.525 | 28 |
| Cell death and survival | Apoptosis of neurons | 0.0000414 | Increased | 3.077 | 39 |
| Gastrointestinal disease, hepatic system disease, organismal injury and abnormalities | Liver lesion | 0.000048 | Increased | 2.594 | 53 |
| Developmental disorder, embryonic development, organismal survival | Death of embryo | 0.0000693 | Increased | 4.258 | 22 |
| Cancer, organismal injury and abnormalities | Epithelial neoplasm | 0.0000849 | Increased | 2.115 | 65 |
| Cancer, organismal injury and abnormalities | Development of carcinoma | 0.0000998 | Increased | 2.229 | 39 |
| Cancer, organismal injury and abnormalities, respiratory disease | Development of lung carcinoma | 0.000105 | Increased | 2.559 | 17 |
| Cancer, organismal injury and abnormalities | Adenocarcinoma | 0.000142 | Increased | 2.587 | 30 |
| Cancer, cell death and survival, organismal injury and abnormalities | Cell death of tumor | 0.000151 | Increased | 3.66 | 30 |
| Cancer, cell death and survival, organismal injury and abnormalities, tumor morphology | Necrosis of tumor | 0.000254 | Increased | 3.66 | 29 |
| Cancer, organismal injury and abnormalities, respiratory disease | Lung adenocarcinoma | 0.000393 | Increased | 2.375 | 15 |
| Cancer, organismal injury and abnormalities, respiratory disease | Non-small cell lung carcinoma | 0.000584 | Increased | 2.559 | 17 |
| Cancer, organismal injury and abnormalities | Adenoma | 0.00077 | Increased | 2.042 | 25 |
| Developmental disorder, embryonic development | Degeneration of embryo | 0.000814 | Increased | 2.804 | 8 |
| Cancer, organismal injury and abnormalities | Carcinoma | 0.00101 | Increased | 2.006 | 48 |
| Developmental disorder, embryonic development, tissue morphology | Degeneration of embryoblast | 0.00135 | Increased | 2.433 | 6 |
| Cancer, cell death and survival, organismal injury and abnormalities, tumor morphology | Cell death of tumor cells | 0.00151 | Increased | 3.536 | 26 |
| Connective tissue disorders, developmental disorder, organismal injury and abnormalities, skeletal and muscular disorders | Dysplasia of skeleton | 0.00204 | Increased | 2.2 | 7 |
| Organismal survival | Perinatal death | 0.00223 | Increased | 6.322 | 60 |
| Developmental disorder, embryonic development, tissue morphology | Degeneration of embryonic tissue | 0.00329 | Increased | 2.63 | 7 |
| Neurological disease, organismal injury and abnormalities | Hydrocephalus | 0.00329 | Increased | 3.138 | 11 |
| Carbohydrate metabolism | Glycolysis of cells | 0.00522 | Increased | 2 | 8 |
| Lipid metabolism, molecular transport, small molecule biochemistry | Concentration of acylglycerol | 0.00562 | Increased | 2.147 | 33 |
| Cellular compromise | Dysfunction of mitochondria | 0.00654 | Increased | 2.213 | 5 |
| Cancer, cell death and survival, organismal injury and abnormalities, tumor morphology | Cell death of cancer cells | 0.00661 | Increased | 3.252 | 20 |
| Cancer, cell death and survival, organismal injury and abnormalities, tumor morphology | Cell death of osteosarcoma cells | 0.00721 | Increased | 3.742 | 14 |
| Cancer, organismal injury and abnormalities | Development of head and neck tumor | 0.00724 | Increased | 2.189 | 11 |
| Cellular assembly and organization, cellular function and maintenance | Organization of cytoskeleton | 6.48E-08 | Decreased | −3.001 | 101 |
| Nervous system development and function, tissue morphology | Quantity of neurons | 0.000000822 | Decreased | −2.239 | 53 |
| Cellular assembly and organization, cellular function and maintenance | Organization of cytoplasm | 0.000000842 | Decreased | −3.001 | 103 |
| Cellular assembly and organization, cellular function and maintenance | Microtubule dynamics | 0.00000115 | Decreased | −3.268 | 86 |
| Cell morphology, cellular assembly and organization, cellular function and maintenance | Formation of cellular protrusions | 0.00000314 | Decreased | −2.624 | 70 |
| Cancer, organismal injury and abnormalities | Growth of tumor | 0.00000351 | Decreased | −3.22 | 75 |
| Cellular movement | Cell movement | 0.00000707 | Decreased | −4.559 | 132 |
| Tissue morphology | Quantity of cells | 0.00001 | Decreased | −3.306 | 171 |
| Cellular growth and proliferation, connective tissue development and function, tissue development | Proliferation of connective tissue cells | 0.0000108 | Decreased | −2.856 | 49 |
| Cellular movement | Migration of cells | 0.0000139 | Decreased | −4.26 | 117 |
| Cellular movement, nervous system development and function | Migration of neurons | 0.0000177 | Decreased | −2.055 | 30 |
| Connective tissue development and function, tissue development | Growth of connective tissue | 0.0000256 | Decreased | −2.686 | 50 |
| Cellular assembly and organization | Quantity of intermediate filaments | 0.000211 | Decreased | −2 | 4 |
| Nervous system development and function | Sensation | 0.00041 | Decreased | −2.482 | 30 |
| Cancer, organismal injury and abnormalities | Neoplasia of tumor cell lines | 0.000582 | Decreased | −2.44 | 15 |
| Cellular development, cellular growth and proliferation, nervous system development and function, tissue development | Development of neurons | 0.000782 | Decreased | −2.282 | 63 |
| Cellular function and maintenance | Cellular homeostasis | 0.000792 | Decreased | −2.034 | 103 |
| Organismal development | Size of animal | 0.00102 | Decreased | −2.322 | 22 |
| Cell-to-cell signaling and interaction, nervous system development and function | Auditory evoked potential | 0.00126 | Decreased | −2.725 | 12 |
| Behavior | Learning | 0.00151 | Decreased | −2.11 | 41 |
| Lipid metabolism, small molecule biochemistry, vitamin and mineral metabolism | Synthesis of steroid hormone | 0.00168 | Decreased | −2.219 | 6 |
| Tissue development | Formation of gland | 0.00313 | Decreased | −2.088 | 25 |
| Embryonic development, organismal development | Development of body trunk | 0.00377 | Decreased | −3.116 | 95 |
| Embryonic development, organ development, organismal development, skeletal and muscular system development and function, tissue development | Formation of muscle | 0.00389 | Decreased | −2.398 | 32 |
| Cancer, organismal injury and abnormalities | Metastasis of tumor cell lines | 0.00431 | Decreased | −2.556 | 10 |
| Organismal development | Development of genitourinary system | 0.0049 | Decreased | −3.43 | 86 |
| Auditory and vestibular system development and function, nervous system development and function | Hearing | 0.00506 | Decreased | −2.157 | 15 |
| Amino acid metabolism,post-translational modification, small molecule biochemistry | Phosphorylation of L-amino acid | 0.00686 | Decreased | −2 | 13 |
|
| |||||
|
|
|
|
|
|
|
| Cellular assembly and organization, cellular function and maintenance | Organization of cytoskeleton | 6.83E-08 | Increased | 2.675 | 101 |
| Cellular assembly and organization, cellular function and maintenance | Organization of cytoplasm | 0.000000884 | Increased | 2.675 | 103 |
| Cellular assembly and organization, cellular function and maintenance | Microtubule dynamics | 0.0000012 | Increased | 2.941 | 86 |
| Cell morphology, cellular assembly and organization, cellular function and maintenance | Formation of cellular protrusions | 0.00000326 | Increased | 2.483 | 70 |
| Cancer, organismal injury and abnormalities | Growth of tumor | 0.00000365 | Increased | 2.325 | 75 |
| Cellular movement | Cell movement | 0.00000746 | Increased | 2.14 | 132 |
| Nucleic acid metabolism | Metabolism of nucleic acid component or derivative | 0.000087 | Increased | 2.209 | 27 |
| Cell morphology, cellular function and maintenance | Autophagy | 0.000186 | Increased | 2.393 | 24 |
| Nucleic acid metabolism, small molecule biochemistry | Metabolism of nucleotide | 0.000212 | Increased | 2.209 | 23 |
| Organismal survival | Viability | 0.000296 | Increased | 3.302 | 14 |
| Nervous system development and function | Sensation | 0.000417 | Increased | 2.058 | 30 |
| Cellular function and maintenance | Cellular homeostasis | 0.000821 | Increased | 2.663 | 103 |
| Organismal development | Size of animal | 0.00104 | Increased | 2.322 | 22 |
| Embryonic development, organismal development | Growth of embryo | 0.00133 | Increased | 2.454 | 46 |
| Cellular movement, embryonic development | Cell movement of embryonic cells | 0.00172 | Increased | 2.2 | 12 |
| Embryonic development, organismal development | Development of body trunk | 0.00389 | Increased | 2.736 | 95 |
| Cancer, organismal injury and abnormalities | Metastasis of tumor cell lines | 0.00434 | Increased | 2.008 | 10 |
| Nervous system development and function, tissue morphology | Quantity of neuroglia | 0.00449 | Increased | 2.402 | 14 |
| Nucleic acid metabolism, small molecule biochemistry | Synthesis of nucleotide | 0.00583 | Increased | 2.019 | 15 |
| Respiratory system development and function | Respiration of mice | 0.00693 | Increased | 2 | 9 |
| Embryonic development, organ development, organismal development, skeletal and muscular system development and function, tissue development | Development of striated muscle | 0.00767 | Increased | 2.236 | 17 |
| Organismal survival | Organismal death | 2.59E-11 | Decreased | −7.796 | 251 |
| Developmental disorder, embryonic development, organismal survival | Death of embryo | 0.0000704 | Decreased | −2.198 | 22 |
| Cancer, cell death and survival, organismal injury and abnormalities | Cell death of tumor | 0.000153 | Decreased | −2.141 | 30 |
| Cancer, cell death and survival, organismal injury and abnormalities, tumor morphology | Necrosis of tumor | 0.000258 | Decreased | −2.141 | 29 |
| Cancer, cell death and survival, organismal injury and abnormalities, tumor morphology | Cell death of tumor cells | 0.00154 | Decreased | −2.363 | 26 |
| Connective tissue disorders, developmental disorder, organismal injury and abnormalities, skeletal and muscular disorders | Dysplasia of skeleton | 0.00205 | Decreased | −2.2 | 7 |
| Organismal survival | Perinatal death | 0.00228 | Decreased | −3.588 | 60 |
| Organismal survival | Death of perinatal stage organism | 0.00619 | Decreased | −2.137 | 11 |
| Cellular compromise | Dysfunction of mitochondria | 0.00657 | Decreased | −2.213 | 5 |
FIGURE 2Protein enrichment analysis by IPA showing types of protein and Comparative heat map. Pie chart showing types of protein mapped by IPA (A), Disease function Heat map of male (B) and female (C) zebrafish brain proteome upon hypoxia treatment.
FIGURE 3Pathway based on the top networks. Comparative heatmap for canonical pathways of male and female brain proteome induced by hypoxia (A), Predictive pathway for zebrafish male (B) and female (C) brain proteome induced by hypoxia, comparative heatmap for upstream regulators (D).
IPA generated upstream regulators analysis for male and female zebrafish brain proteome induced by hypoxia following recovery.
|
| |||||||||||
|
|
|
|
|
|
|
| |||||
| 1 | MYC | Transcription regulator | Inhibited | −2.24 | 4.52E-05 | BUB1, CCNA2, ENO1, EZH1, GLS, GOT1, GOT2, GPI, HIF1A, LDHB, MCM6, MCM7, PA2G4, PDHA1, PDK1, PGAM1, PGK1, PKM, TCF3 | |||||
| 2 | RB1 | Transcription regulator | Inhibited | −3.183 | 0.000472 | ACO2, Actn3, APAF1, ATP1A1, ATP5F1A, BCKDHA, CASP9, CCNA2, CKM, DLST, FABP2, HSBP1, KRT18, MCM7, MFN2, MLYCD, MYH4, MYH6, MYH7, NDUFB10, RBL1, TIMM22 | |||||
| 3 | TSC2 | Other | Inhibited | −2.433 | 0.000695 | IRS1, IRS2, MCL1, PDGFRB, PRKCA, PSMC3 | |||||
| 4 | CSF2 | Cytokine | Inhibited | −3.141 | 0.00347 | BUB1, C3, CCNA2, CHTF18, E2F8, EXO1, FBXO5, FIGNL1, IL12B, KNTC1, MCM6, MNS1, NOS2, POLD1, POLE, SMC2, TLR4 | |||||
| 5 | MKNK1 | Kinase | Inhibited | −3.317 | 0.00792 | APC, ATP1A3, CRMP1, DPYSL3, HADHA, KIF5A, MYO6, PRKAR1B, SNAP25, STXBP1, THRA | |||||
| 6 | Gsk3 | Group | Inhibited | −2.219 | 0.00826 | COL2A1, KDR, MYH6, NOS2, STAT1 | |||||
| 7 | NFE2L2 | Transcription regulator | Inhibited | −2.066 | 0.00931 | ACTG1, ALAS2, APOA4, ATP1A1, CDKN2C, ESD, FKBP5, G6PD, GFAP, GSTP1, HMOX1, L1CAM, MCFD2, NCKAP1, NOS2, NQO1, PDIA3, PFN2, PSMC1, PSMC3, PSMD11, RAN, SCG2, SREBF1, SYP, TTR, VCP | |||||
| 8 | THRB | Ligand-dependent nuclear receptor | Inhibited | −3.054 | 0.0121 | ABCD3, CSHL1, DDC, DIO1, FGFR3, IGFBP2, MAPK8, MYH6, MYH7, NCOR2, STAT5B, WNT4, YWHAE | |||||
| 9 | LEPR | Transmembrane receptor | Inhibited | −2.791 | 0.0139 | APOA1, APOA4, CREB3L2, CSHL1, EXOC4, GFAP, HIF1A, INPPL1, IRS2, MMP14, NBN, PLCB3, SNAP25, SREBF1 | |||||
| 10 | IL1B | Cytokine | Inhibited | −2.59 | 0.0182 | A2M, ATP1A1, C3, COL2A1, FKBP5, FOXO1, HAS2, HIF1A, KIF15, MMP9, NOS2, STAT1 | |||||
| 11 | EGFR | Kinase | Inhibited | −2.314 | 0.0258 | ACY1, ATAD3A, CCNA2, CCT5, GFAP, HAS2, MMP14, MMP9, PA2G4, TUBA4A, UBA1 | |||||
| 12 | OTX2 | Transcription regulator | Inhibited | −2.219 | 0.0435 | A2M, EN1, PRDM1, SIX3, TF, TTR | |||||
| 13 | UCHL1 | Peptidase | Inhibited | −2 | 0.366 | ANXA6, LDHB, MAPK6, SCP2 | |||||
| 14 | STAT6 | Transcription regulator | Inhibited | −2.433 | 1 | BCL6, Cmah, IL12B, IRS2, MMP14, MMP9, MYO6, NCOA3, SERPINA1 | |||||
| 15 | KDM5A | Transcription regulator | Activated | 2.688 | 0.00249 | ACO2, Actn3, ATP1A1, ATP5F1A, BCKDHA, DLST, HSBP1, MFN2, MLYCD, MYH4, MYH6, MYH7, NDUFB10, TIMM22 | |||||
| 16 | 26s Proteasome | Complex | Activated | 2.236 | 0.00826 | APAF1, BHLHE22, FOXO1, NOTCH1, PRKCA | |||||
| 17 | HAND1 | Transcription regulator | Activated | 2 | 0.0179 | KDR, MLYCD, NOTCH1, NRP1 | |||||
| 18 | SATB1 | Transcription regulator | Activated | 2 | 0.472 | APC, ETS1, NCOR1, NR2C2 | |||||
|
| |||||||||||
|
|
|
|
|
|
|
| |||||
| 1 | MYC | Transcription regulator | Activated | 2.801 | 4.58E-05 | BUB1, CCNA2, ENO1, EZH1, GLS, GOT1, GOT2, GPI, HIF1A, LDHB, MCM6, MCM7, PA2G4, PDHA1, PDK1, PGAM1, PGK1, PKM, TCF3 | |||||
| 2 | INSR | Kinase | Activated | 2.124 | 0.000466 | ACO2, ACTA1, ACTN4, ALDH6A1, ATP5F1A, ATP5F1B, CS, DCTN4, FLNC, GOT2, HADHA, HSPD1, IDH3A, IGF2R, INSR, MDH2, MMP9, MPEG1, MYH7, NAMPT, OGDH, PDHA1, PDHB, PKLR, SCP2, SREBF1 | |||||
| 3 | Gm21596/Hmgb1 | Transcription regulator | Activated | 2.219 | 0.00101 | HIF1A, NOS2, PKM, SIGIRR, TLR4 | |||||
| 4 | PIK3R1 | Kinase | Activated | 2.621 | 0.00711 | FOXO1, HIF1A, HMOX1, IL12B, NOS2, PDHA1, PDK1, PKM | |||||
| 5 | MKNK1 | Kinase | Activated | 2.111 | 0.00798 | APC, ATP1A3, CRMP1, DPYSL3, HADHA, KIF5A, MYO6, PRKAR1B, SNAP25, STXBP1, THRA | |||||
| 6 | NFE2L2 | Transcription regulator | Activated | 2.705 | 0.00943 | ACTG1, ALAS2, APOA4, ATP1A1, CDKN2C, ESD, FKBP5, G6PD, GFAP, GSTP1, HMOX1, L1CAM, MCFD2, NCKAP1, NOS2, NQO1, PDIA3, PFN2, PSMC1, PSMC3, PSMD11, RAN, SCG2, SREBF1, SYP, TTR, VCP | |||||
| 7 | EGR3 | Transcription regulator | Activated | 2.219 | 0.0116 | BCL6, ESD, LMO7, NOTCH1, PABPC1L | |||||
| 8 | THRB | Ligand-dependent nuclear receptor | Activated | 3.054 | 0.0122 | ABCD3, CSHL1, DDC, DIO1, FGFR3, IGFBP2, MAPK8, MYH6, MYH7, NCOR2, STAT5B, WNT4, YWHAE | |||||
| 9 | MYB | Transcription regulator | Activated | 2 | 0.019 | CLTA, HSPA8, MAD1L1, NOTCH1, RGS8, SLC27A2, TULP4 | |||||
| 10 | OTX2 | Transcription regulator | Activated | 2.219 | 0.0437 | A2M, EN1, PRDM1, SIX3, TF, TTR | |||||
| 11 | SRF | Transcription regulator | Activated | 2.957 | 0.0551 | ACTA1, ACTG1, CKM, ETS1, ITGA2B, ITGB1, KDR, MYH4, MYH6, MYH7, PRSS57, TTN, VCL | |||||
| 12 | HIF1A | Transcription regulator | Activated | 2.008 | 0.165 | ENO1, IL12B, MIF, NOS2, NOTCH1, PDHA1, PDK1, PKM, TTN | |||||
| 13 | HOXD10 | Transcription regulator | Activated | 2 | 0.193 | DAPP1, RSAD2, TFR2, WDR5 | |||||
| 14 | Creb | Group | Activated | 2 | 0.296 | ARHGEF9, CBWD1, GABBR1, GRK3, INTS7, MCL1, PGK1, POLE, PRKCA | |||||
| 15 | HNF4A | Transcription regulator | Activated | 2.382 | 0.329 | CCNA2, ELMO1, FABP2, HIF1A, HSPA8, KRT8, NBEA, PFN2, PKM, RSPH4A, SCP2, SERPINA1, TF, TFR2, WNT4 | |||||
| 16 | mir-223 | MicroRNA | Activated | 2 | 1 | ALCAM, CRHBP, NQO1, TLR4 | |||||
| 17 | DNMT3B | Enzyme | Inhibited | −2.53 | 0.00754 | ACTA1, CKM, GRK3, KDR, MYH6, MYH7, PIK3C2B, PRKAR1B, SLC8A2, STAT1 | |||||
| 18 | MAT1A | Enzyme | Inhibited | −2 | 0.0149 | APOA1, KRT18, MAT1A, PRDX6 | |||||
| 19 | CHADL | Other | Inhibited | −2 | 0.061 | COL2A1, CSPG4, MN1, NTRK3 | |||||
| 20 | PTPN1 | Phosphatase | Inhibited | −2.219 | 0.0762 | HHEX, IRS1, IRS2, NOS2, TMEM26 | |||||
| 21 | DNMT3A | Enzyme | Inhibited | −2.121 | 0.142 | ACTA1, CKM, GRK3, IRS1, MYH6, MYH7, PIK3C2B, SLC8A2 | |||||
| 22 | ZNF106 | Other | Inhibited | −2 | 0.204 | ALAS2, C3, NDUFB10, PRDX2 | |||||
| 23 | BTNL2 | Transmembrane receptor | Inhibited | −2 | 0.55 | CDKN2C, DAPP1, NTRK3, S100A4 | |||||
| 24 | DICER1 | Enzyme | Inhibited | −2.138 | 1 | CCNG1, CRH, ERBB2, HNRNPH1, IGF2R, ITGB1, MMP9, NOTCH1, PRKCA | |||||
IPA generated regulatory effect analysis for male and female zebrafish brain proteome induced by hypoxia following recovery.
| Male hypoxia regulator effects | ||||||||
|---|---|---|---|---|---|---|---|---|
| ID | Consistency score | Regulators | Target total | Target molecules in dataset | Diseases & functions | Known regulator-disease/function relationship | ||
| 1 | 2.309 | HAND1,THRB | 12 | CSHL1,FGFR3,IGFBP2,KDR,MAPK8,MLYCD,MYH6,NCOR2,NOTCH1,NRP1,STAT5B,WNT4 | Cellular homeostasis, development of body trunk, development of genitourinary system | 67% (4/6) | ||
| 2 | 2.111 | MYC | 11 | BUB1,CCNA2,ENO1,GLS,GPI,HIF1A,PA2G4,PDHA1,PDK1,PKM,TCF3 | Carcinoma, frequency of tumor, growth of tumor, incidence of tumor | 100% (4/4) | ||
| 3 | 2 | NFE2L2 | 4 | PSMC1,PSMD11,RAN,VCP | Cell death of tumor cells | 0% (0/1) | ||
| 4 | 1.789 | OTX2 | 5 | A2M,EN1,PRDM1,SIX3,TF | Quantity of cells | 100% (1/1) | ||
| 5 | −5.715 | MYC | 6 | ENO1,GPI,HIF1A,PDK1,PGK1,PKM | Glycolysis of cells | 100% (1/1) | ||
| 6 | −7.506 | HAND1 | 3 | KDR,NOTCH1,NRP1 | Migration of cells | 0% (0/1) | ||
| 7 | −16.743 | HAND1 | 3 | KDR,NOTCH1,NRP1 | Organization of cytoplasm | 0% (0/1) | ||
| 8 | −19.23 | MYC | 5 | BUB1,CCNA2,GPI,HIF1A,PDK1 | Growth of connective tissue | 100% (1/1) | ||
|
| ||||||||
|
|
|
|
|
|
|
| ||
| 1 | 3.051 | Gm21596/Hmgb1,PIK3R1,THRB | 13 | CSHL1,FGFR3,FOXO1,HIF1A,HMOX1,IL12B,MAPK8,MYH6,NCOR2,NOS2,STAT5B,TLR4,WNT4 | Autophagy, development of body trunk | 50% (3/6) | ||
| 2 | −4.082 | MKNK1 | 6 | ATP1A3,HADHA,KIF5A,SNAP25,STXBP1,THRA | Perinatal death | 0% (0/1) | ||
| 3 | −4.491 | PIK3R1 | 6 | FOXO1,HIF1A,HMOX1,IL12B,NOS2,PDK1 | Cell movement | 100% (1/1) | ||
| 4 | −5.367 | MKNK1 | 5 | APC,CRMP1,DPYSL3,KIF5A,MYO6 | Microtubule dynamics | 0% (0/1) | ||
| 5 | −6.5 | Gm21596/Hmgb1 | 4 | HIF1A,NOS2,PKM,TLR4 | Growth of tumor | 100% (1/1) | ||
| 6 | −7.5 | NFE2L2 | 4 | G6PD,NOS2,NQO1,VCP | Metabolism of nucleotide | 0% (0/1) | ||
FIGURE 4Validation of few regulatory target molecules. Graph showing mRNA expression of eno1, foxo1, gp1, hmox1, nos2, pkm, ran, and vcp (A) The data are expressed as the mean ± SEM, (n = 6 pooled brains). Immunoblot showing expression of pCREB and pAKT in male and female brain (B), Densitometry for comparison of protein expression in HM vs. NM and HF vs. NF (C).
Top 5 upregulated proteins retrieved from uniformly regulated (upregulated) in both male and female zebrafish brain induced by acute hypoxia.
|
|
|
|
|
|
| 1 | 56693350 | Very long-chain acyl-CoA synthetase | 3.234 | 1.690 |
|
|
|
|
|
|
| 3 | 189531944 | Predicted: hypothetical protein LOC100148665 | 3.057 | 1.966 |
| 4 | 326666355 | Predicted: zinc finger protein 208-like | 2.984 | 2.606 |
| 5 | 326664965 | Predicted: protein FAM5C | 2.742 | 3.703 |
H3K9 which was the focus of manuscript and taken for further mechanistic analysis so made it bold.
FIGURE 5Deciphering the role of H3K9me3 by co-immunoprecipitation. Immunoblot of H3K9me3 showing upregulation in hypoxia (A), CoIP of H3K9me3 in zebrafish male brain nuclear protein (B), Schematic representation of CoIP analysis (C). ChIP qPCR showing H3K9 occupancy on target gene promoter. ChIP qPCR showing the increase in H3K9me3 enrichment on the promoter region of klf4, sox2, and nestin in hypoxic male brain (D).
FIGURE 6Validation ChIP analysis. mRNA expression at 4 h (A) and 10 h (B) post hypoxia in both male and female (n = pooled 6 brain). Expression of sox2 protein at different times of recovery from hypoxia (C). Expression of H3K9me3 at different times of recovery from hypoxia (D).